BLMs 4 TB SIGNED
Beta-lactams for Tuberculosis Treatment
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0BLMs 4 TB project word cloud
Explore the words cloud of the BLMs 4 TB project. It provides you a very rough idea of what is the project "BLMs 4 TB" about.
Project "BLMs 4 TB" data sheet
The following table provides information about the project.
| Coordinator |
FUNDACION AGENCIA ARAGONESA PARA LA INVESTIGACION Y EL DESARROLLO
Organization address contact info |
| Coordinator Country | Spain [ES] |
| Total cost | 170˙121 € |
| EC max contribution | 170˙121 € (100%) |
| Programme |
1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility) |
| Code Call | H2020-MSCA-IF-2016 |
| Funding Scheme | MSCA-IF-EF-SE |
| Starting year | 2018 |
| Duration (year-month-day) | from 2018-04-01 to 2020-03-31 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | FUNDACION AGENCIA ARAGONESA PARA LA INVESTIGACION Y EL DESARROLLO | ES (ZARAGOZA) | coordinator | 170˙121.00 |
Map
Project objective
Tuberculosis (TB) is the most deadly infectious disease worldwide. TB therapy takes 6 months with unpleasant side effects that leads to poor adherence and the development of drug resistance. Patients infected with multi (MDR) or extensively (XDR) drug resistant strains must undergo longer treatments (up to 24 months) associated with even severe side effects and only 30-50% positive treatment outcomes. New treatments are urgently needed.
Beta-lactams (BLMs) are the safest antibiotics in the market with a long track record of clinical use to treat bacterial infections. They were, however, traditionally regarded as ineffective for TB therapy to the point that research was virtually discontinued for the last three decades. A renewed interest recently arose after a report of Phase IIa clinical trial validated the potential of meropenem (a carbapenem). This study was led by Dr. Barros, Head TB unit GlaxoSmithKline (GSK) (the beneficiary of this proposal). In addition, Dr. Ramón-García (the applicant) just identified first-generation cephalosporins (cephems), a subset of the BLM family never pursued for TB therapy, as potential anti-TB agents. Promoting BLM development is the best immediate hope for TB patients that currently have very dim life prospects.
Carbapenems and cephems have different anti-bacterial killing properties, pharmacokinetic (PK) and pharmacodynamics (PD) parameters. These specificities affect therapy design for an optimal clinical outcome. Although promising, it is still unclear how BLMs should be included in new combo therapies (i.e. dosage, duration and frequency of administration) to shorten the duration of TB therapy, prevent relapse and treat M(X)DR-TB.
To answer these questions, I will use time-lapse microscopy linked to mathematical PK/PD modeling, transcriptomic and proteomic studies and clinical microbiology techniques to provide high quality molecular and PK/PD pre-clinical data to inform the design of future BLM TB clinical trials.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BLMS 4 TB" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "BLMS 4 TB" are provided by the European Opendata Portal: CORDIS opendata.
More projects from the same programme (H2020-EU.1.3.2.)
MacMeninges (2019)
Control of Central Nervous Sytem inflammation by meningeal macrophages, and its impairment upon aging
Read More